Fewer Headache Days Reported With Investigational Treatment

NATIONAL HARBOR, Md. — People with chronic migraines who received multiple sphenopalatine ganglion blocks utilizing 0.5% bupivacaine delivered through a nasal applicator device reported fewer headache days, according to research presented at the American Academy of Pain Medicine Meeting held here recently. 

The research, presented in a poster by Roger Cady, MD,  and his colleagues was derived from two centers, and included 55 chronic migraine patients, ages 18 to 67, who were asked to complete a “headache diary” for about a month, and then randomly assigned to either receive the solution or a saline shame solution. 

The researchers noted that in addition to fewer headache days, the participants in the study reported reductions in overall pain, and improvement in mood and activity levels. 

Clinvest is one of several headache treatment centers throughout the United States that are also looking at sphenopalatine ganglion for cluster headache, as part of the the Pathway CH-2 cluster headache clinical study.The study is evaluating the ATI Neurostimulation System, an investigational device designed to provide targeted cluster headache relief.

For more information, please call 417-883-7889. 

Reference

1. Cady R. et al. “Long Term Efficacy of Repetitive Sphenopalatine Blockade with Bupivacaine 
vs. Saline with the Tx360 Device for Treatment of Chronic Migraine.”Presented at: AAPM Annual Meeting. March 19-22, 2015; National Harbor, Maryland.